“In Q2, we demonstrated the power of our platform with high impact clinical results, publication of key clinical findings, and competitive, non-dilutive, federal funding,” said Jennifer Buell, Ph.D., President and Chief Executive Officer of MiNK Therapeutics (INKT). “Since quarter-end, we further strengthened our financial position that extends our runway beyond mid-2026. With our cash position, coupled with two separate non-dilutive grants for the clinical advancement of allo-INKTs in GvHD – we can achieve substantial clinical program advancements.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INKT:
- Mink Therapeutics, Inc. (INKT) Q2 Earnings Cheat Sheet
- H.C. Wainwright downgrades MiNK Therapeutics after 400% rally
- MiNK Therapeutics downgraded to Neutral from Buy at H.C. Wainwright
- MiNK Therapeutics announces publication of article on CAR-iNKT in Frontiers
- MiNK Therapeutics Enters $50M Sales Agreement with B. Riley